Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer

Inclusion Criteria: * Patients with histologically confirmed MAIPC * Documented progressive disease in bone, soft tissue or PSA despite castrate levels of testosterone * If LHRH agonist were used previously it must be kept * Previous anti-androgen should be held at least 4 weeks for flutamida or cyproterone and 6 weeks for bycalumida * Previous DES should be held for at least 4 weeks before partcipating in the trial * Chemotherapy naive patients * No prior radioisotope * Less than 25% of bone marrow should be irradiated for prior palliative radiotherapy * KPS\> 70% * Adequate hematologic, hepatic and renal function Exclusion Criteria: * Patients with serious medical illness * History of significant active cardiac disease * History of gastrointestinal ulceration, bleeding or perforation * History of myocardial infarctin within past 12 months * Allergy to sulfonamides or to celecoxib or history of urticaria to any NSAID The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.